Sequence variation in DNA regulatory elements is hypothesized to contribute substantially to risk for common diseases. Variants associated with human disease by GWAS predominantly lie in non-coding genomic regions^[@R1]^ and occur within putative regulatory elements far more often than expected by chance^[@R2],[@R3]^, suggesting that disruption of regulatory function is a common mechanism by which non-coding sequence variants contribute to human disease. Linkage disequilibrium (LD), and the absence of regulatory vocabularies, complicates the discrimination of regulatory risk variants from other variation within disease-associated intervals. Therefore there is a pressing need for methods to predict the impact of regulatory sequence variation, expediting targeted functional validation and the exploration of disease-implicated pathways. However, few formal computational methods have been developed to predict the impact of Single Nucleotide Polymorphisms (SNPs) on regulatory element activity^[@R4],[@R5]^.

Regulatory elements modulate the expression of their target genes through direct binding of sequence-specific transcription factors (TFs)^[@R6]^. While consensus on the mechanisms of regulatory element activity is emerging, we lack a predictive model capable of (1) specifying the cell types and environmental conditions under which an element would modulate the expression of its target gene(s), and (2) describing how specific mutations to that sequence would influence its activity. Here, we develop a computational model that addresses the latter: given a regulatory element active in a specific cell type, compute the effect of a given DNA sequence variation within the element. When trained on a set of putative regulatory sequences, our established gapped *k*-mer Support Vector Machine (gkm-SVM)^[@R7]^ identifies sequence features within these regulatory regions which determine their cell-type dependent activity. We then use this gkm-SVM to quantify the effect of sequence changes within regulatory elements via a metric we term deltaSVM (See overview in [Fig. 1](#F1){ref-type="fig"}). In this systematic, quantitative approach we leverage high quality catalogs of human regulatory elements, generated using DNase I Hypersensitivity, distinctive histone modifications, and TF binding^[@R8],[@R9]^. For example, if the gkm-SVM is trained on DNaseI Hypersensitive Sites (DHSs), it identifies the sequence features that determine chromatin accessibility in the corresponding cellular context. Our method is, however, blind to extant databases or binding motif data, and consequently can uncover novel motifs, combinatorial constraints, and key accessory factors, and quantify the significance of their individual contributions to regulatory element activity.

Results {#S1}
=======

Model training and validation {#S2}
-----------------------------

We previously demonstrated that a properly trained SVM can predict cell-type specific regulatory elements from primary genome sequence alone^[@R7],[@R10]--[@R12]^. To test whether this SVM-based approach could be adapted to predict the functional consequence of sequence variation within regulatory elements, we first took advantage of a large set of dsQTLs (DNase I Sensitivity Quantitative Trait Loci) identified in a collection of human Lymphoblastoid Cell Lines (LCLs)^[@R13]--[@R15]^. These are SNPs within putative regulatory regions (marked by DNase I Hypersensitivity) and are associated with altered DNase I sensitivity therein. We first trained a gkm-SVM on the top DHSs in the LCL GM12878^[@R8]^. The gkm-SVM produces a scoring function characterized by a set of weights quantifying the contribution of each possible 10-mer to a region's DNase I sensitivity in GM12878 cells. We then can calculate deltaSVM, the predicted impact of any Single Nucleotide Variant (SNV) on chromatin accessibility in LCLs, by summing the change in weight between alleles for each of the ten 10-mers encompassing the SNV, as shown in [Fig. 2a](#F2){ref-type="fig"} for the dsQTL rs4953223^[@R13]^. Here, the indicted SNP allele disrupts a NF-κB binding site, which in our model reduces the strong positive contribution of several 10-mers. Two neighboring SNPs do not make significant changes to the weights, as shown graphically in [Fig. 2b](#F2){ref-type="fig"}, and the score of each allele is the sum of the weights across this region. Similarly, we can extend this method to INDELs and multiple substitutions by summing weights across all affected bases.

To systematically assess the ability of deltaSVM to predict the impact of SNPs on DNase I sensitivity, we compared deltaSVM to the set of dsQTLs^[@R13]^, quantified by the effect-size, beta. The correlation between deltaSVM and effect-size for the 579 SNPs within 100 bp of a DHS is highly significant, with a Pearson correlation coefficient C = 0.721 (t-distribution *P* = 7.68e-94) ([Fig. 2c](#F2){ref-type="fig"}). This correlation falls off rapidly with distance ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}), thus our analysis is consistent with local action of dsQTLs. However, if our predictions are accurate, deltaSVM analyses on non-dsQTL SNPs should also yield low scores in order to limit false positive predictions. We chose a 50x larger negative set of non-dsQTL SNPs with comparable levels of DNase I sensitivity as a negative set, since there are typically 50--100 SNPs within a single LD block^[@R15]^. In [Fig. 2d](#F2){ref-type="fig"} we show the Receiver Operating Characteristic (ROC) curve, plotting True Positive rate (TP/P) vs. False Positive rate (FP/P), and in [Fig. 2e](#F2){ref-type="fig"} we show the Precision-Recall (PR) curve, plotting precision (true positives over predicted positives, TP/PP = TP/(TP+FP)) vs. recall (TP/P), for our method (gkm-SVM deltaSVM) compared to four other methods^[@R4],[@R5],[@R10],[@R16]^.

Here, as is typically the case for genomic predictions where the search space is large, the lower left corner of the ROC curve, where the FP rate is low, has the most dramatic effect on the accuracy (precision) of the predictions^[@R17]^. At a recall of 10%, the gkm-SVM predictions are 55.9% accurate, \~5x more accurate than deltaSVM based on smaller 6-mers (kmer-SVM)^[@R10]^ as shown in [Fig. 2e](#F2){ref-type="fig"}, because while the kmer-SVM can predict full regions very accurately by averaging many weights, the kmer weights needed to evaluate SNPs are determined from a small set of support vectors and are noisy. By contrast the gkm-SVM reduces the false positive rate significantly by using much more statistically robust gapped-kmer weights^[@R18]^. Additionally, in comparison to conservation (GERP score^[@R16]^), and to two recently published methods integrating functional genomic datasets to predict the deleteriousness of noncoding variants (CADD^[@R4]^ and GWAVA^[@R5]^) the gkm-SVM is ≥ 10x more accurate than any of these existing methods at 10% recall ([Fig. 2e](#F2){ref-type="fig"}).

Three key features contribute to our dramatically improved accuracy. First, we train gkm-SVM on set of regulatory elements whose activity is specific to the relevant cell type. Second, this large training set (thousands) includes both positive and negative elements to statistically determine the DNA sequence elements required for activity, rather than relying on the precise state of any specific regulatory element in a specific assay. Thirdly, we identify a complete catalog of both *positive* and *negative* sequence features, as many SNPs result in a significant deltaSVM based on what the variant changes *to*, rather than what it *was* in the reference/assayed genome. In our discriminative approach, gkm-SVM identifies these negative sequence elements by their presence in the negative set and their absence in the positive set. This is critical for accurately assessing the effect of variants, as many of our predicted functional SNPs modulate intermediate strength binding sites.

Ultimately we are interested in how a variant modulates the expression of its target genes. 125 of 579 dsQTLs are also eQTLs^[@R19]^ (variants associated with differential gene expression), but some dsQTLs are anti-correlated with eQTLs^[@R13]^. Both classes of dsQTLs are strongly positively correlated with deltaSVM ([Fig. 3a--c](#F3){ref-type="fig"}). Thus surprisingly, but consistent with earlier analysis^[@R13]^, we find that as 22% of the dsQTLs become more accessible, they repress target gene expression. We also analyzed the relationship between deltaSVM and evolutionary sequence conservation. Interestingly, although bases predicted to either reduce or increase DNase I sensitivity when mutated are more conserved than bases predicted to be neutral, we found that negative deltaSVM bases are much more conserved than positive deltaSVM bases ([Fig. 3d](#F3){ref-type="fig"} and [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}).

gkm-SVM predicts functional impact of enhancer variants {#S3}
-------------------------------------------------------

To directly test the ability of our SVM-based approach to predict the functional consequence of sequence variation on enhancer activity, we first turned to well-characterized enhancers of the pigmentation genes *Tyr* and *Tyrp1*^[@R20],[@R21]^ ([Fig. 4a,b](#F4){ref-type="fig"}). We trained a melanocyte-specific gkm-SVM on a large set of putative melanocyte enhancers marked by EP300 and H3K4me1^[@R12]^, and scored all possible SNVs in the *Tyr* and *Tyrp1* enhancers, selecting and synthesizing more than 40 SNVs, across a range of deltaSVM scores, and tested each variant independently in luciferase reporter assays. For both enhancers, deltaSVM is strongly correlated with the observed difference in luciferase reporter activity between mutant and wild-type enhancer constructs (Pearson C = 0.778, P \< 2e-5 for *Tyr*, and C = 0.529, P \< .0095 for *Tyrp1*; [Fig. 4c,d](#F4){ref-type="fig"}).

Despite their depth, our analyses of the *Tyr* and *Tyrp1* enhancers tested only a subset of all possible variants therein, and relied on *in vitro* reporter assays. Therefore, we turned to a dataset in which all possible variants within a 259 bp liver-specific enhancer of the *ALDOB* gene were tested using a massively parallel reporter assay *in vivo* in mouse liver^[@R22]^. We trained a gkm-SVM on large set of putative liver enhancers marked by DNase I hypersensitivity and H3K4me1 signal in adult mouse liver^[@R23]^. We then compared deltaSVM for each of the tested mutant regions to the observed functional output. Again we see a very high correlation (C = 0.630, P \< 3.24e-81) between the predicted impact of the mutation using our sequence-based model and the observed change in enhancer activity relative to wild-type sequence ([Fig. 5a](#F5){ref-type="fig"}). If we further use the "aggregate score" model^[@R22]^ averaging deltaSVM for each of the 3 possible base substitutions, this correlation reaches C = 0.691 ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}).

We next asked how deltaSVM performed predicting functional variants in diverse sets of enhancers. We analyzed data from another massively parallel reporter assay using targeted mutation of enhancers predicted to be active in K562 and HepG2 cells^[@R24]^. For each wild-type construct that was expressed significantly in either cell line, we separately scored all 1 bp and motif scrambling mutations using a gkm-SVM trained on K562 and HepG2 DHS regions^[@R8]^, and compared the measured expression change to the predicted deltaSVM score in each cell line ([Fig. 5b,c](#F5){ref-type="fig"}). For both datasets again we find high correlation (C = 0.626, P \< 1.34e-31 for K562 and C = 0.646, P \< 3.84e-34 for HepG2). Since all elements were tested and scored in both cell types, this high correlation underscores the accuracy of deltaSVM's cell-type specific predictions and is further supported by the low correlation of deltaSVMs scores from gkm-SVMs trained on non-relevant cell-types ([Table 1](#T1){ref-type="table"}).

Causal SNP predictions for human disease {#S4}
----------------------------------------

In a final test of its potential, we asked whether deltaSVM could predict the functional consequences of studied disease-associated sequence variants. We compared deltaSVM values for three experimentally validated SNPs, each of which has been shown to alter expression leading to increased disease risk or pertinent traits: *Rfx6* (rs339331, prostate cancer)^[@R25]^, *Bcl11a* (rs1427407, fetal hemoglobin levels)^[@R26]^, and *Sort1* (rs12740374, LDL cholesterol levels)^[@R27]^. We trained three separate gkm-SVMs with DHSs from cell lines appropriate to each phenotype (LNCaP, mouse MEL, and HepG2 hepatocytes). We then scored all loci with deltaSVM trained on all three cell-types. In each case, we found that the validated SNPs are only scored higher than flanking SNPs when deltaSVM was trained on the appropriate cell type ([Fig. 6a](#F6){ref-type="fig"}). Specifically, the SORT1 variant only has high deltaSVM when trained on HepG2 cells, relevant for liver, as shown in the 3rd column of [Figure 6a](#F6){ref-type="fig"}.

Since the set of these validated regulatory SNPs is limited, we next examined 413 SNPs associated with 11 autoimmune diseases enriched in T helper cell type 1 (Th1) H3K27Ac regions^[@R28]^. We similarly trained a gkm-SVM on Th1 DHSs^[@R8]^, and for each disease associated locus, scored the lead SNPs and an additional 2700 SNPs in tight LD (as defined in methods), and random SNPs including equivalent size flanking sets as a control. An example locus in *BACH2*, associated with several autoimmune diseases, is shown in [Fig. 6b](#F6){ref-type="fig"}. We identified high scoring deltaSVM SNPs for 17 independent disease associations ([Table 2](#T2){ref-type="table"}), which we predict to be expression perturbing SNPs with high confidence (P \< .02), while at this threshold random sampling produced 8 SNPs ([Fig. 6c](#F6){ref-type="fig"}, [Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). Most of these high scoring SNPs are not the lead SNP, and thus represent novel predictions for the causal SNP.

Discussion {#S5}
==========

One of the most significant challenges facing contemporary genetics and precision medicine is the interpretation of noncoding sequence variation. This challenge remains in the face of significant advances in genome sequence technologies that now make possible the generation of huge quantities of noncoding sequence data. Despite the wealth of evidence linking noncoding sequence variation to disease risk, we have been left wanting in our ability to directly interpret primary noncoding sequence data and hence to infer the biological consequences of disease-associated variation. Our efforts in this study take significant strides in creating a framework within which we can computationally develop and utilize regulatory lexicons, making robust predictions of the consequences of variation in functional noncoding sequence modules.

To ensure very high confidence predictions, we have limited our initial analyses to the highest deltaSVM scores in [Table 2](#T2){ref-type="table"}. However, comparison with validated SNPs ([Fig. 6a](#F6){ref-type="fig"}) shows that many more moderate deltaSVM scoring SNPs will also perturb regulatory activity, but likely with relatively diminished effect. In this sense our random control sampling is highly conservative, as the positive loci are all known to be associated with disease. The high accuracy and low false positive rate of deltaSVM ([Fig. 2e](#F2){ref-type="fig"}) is crucial to identify these causal SNPs with high accuracy. Together with our observations at lymphoblastoid dsQTLs, the *Tyr* and *Tyrp1* enhancers, the *ALDOB* enhancer analyses and those performed in K562, and HepG2, these results clearly demonstrate that deltaSVM can broadly predict the empirically measured, cell-type specific functional consequences of enhancer sequence variants, given an appropriate training substrate.

Our results strongly support the hypothesis that non-coding disease associated SNPs that disrupt DNase HS/enhancer function do so directly through modulation of local TF-DNA interactions, leading to concomitant changes in chromatin state and gene expression. Many of these sequence determinants are recognizable as TF binding sites. Additionally gkm-SVM is also in principle capable of capturing sequence determinants of structural properties of TF-DNA interactions e.g. constrained sequence flanking TFBS that may contribute to the activity or stability of the enhancer/promoter regulatory complex. Precise variant evaluation requires an accurate assessment of the relative contribution of moderate and weak binding sites or other variants which affect chromatin accessibility, which we estimate requires at least \~1000 training elements and a robust classifier. We have shown that these sequence features are robust predictors of chromatin accessibility, and are also predictive of gene expression changes when enhancer/promoter connections are established. But chromatin accessibility is sometimes negatively correlated with gene expression changes, and our results suggest that enhancer/enhancer and enhancer promoter interactions at a larger scale will ultimately determine a sequence variant's impact on gene expression.

In its application, both gkm-SVM and deltaSVM reinforce the recognized importance of cell type, developmental time, and biological state when connecting disease mechanisms to molecular events. Here, the biological state defines a set of active nuclear TFs in the cell, which in turn map sequence features to their target regulatory elements through combinatorial binding. It's understandable therefore that the predictive power of deltaSVM for a given variant indicted in any given disease process is heavily dependent on the availability a biologically appropriate substrate on which to train the gkm-SVM. Consistent with this expectation, we have demonstrated that deltaSVM predictions are highly cell type dependent, i.e. deltaSVM from weights trained on one cell type are weak predictors of expression changes in other cell types ([Table 1](#T1){ref-type="table"}). Further, deltaSVM only identifies the validated disease associated SNPs shown in [Fig. 6a](#F6){ref-type="fig"} if trained on an appropriate cell type. While the ENCODE^[@R8],[@R23]^ and Roadmap^[@R9]^ projects have provided a wealth of such training data, our results indicate that future progress in common disease etiology will be greatly facilitated by coupling sequence based computational analysis with the generation of functional genomics data targeting disease relevant developmental stages and cell types. What we provide here is evidence that such integration of computational and disease-informed biological and strategies can be used to illuminate the roles played by noncoding regulatory variation in disease.

Materials and Methods {#S6}
=====================

gkm-SVM and deltaSVM {#S7}
--------------------

We trained a gkm-SVM by following previously reported methods with minor modifications^[@R7],[@R10]--[@R12]^. Briefly, we first defined a positive training set by using publically available DnaseI-seq and ChIP-seq datasets, as discussed in greater detail below. We then generated a negative training set by randomly sampling from the genome equal number of regions that match length, GC and repeat fractions of the positive set. To remove false negative regions as much as possible, we excluded any regions with P \< 1e-5 (MACS^[@R43]^) from sampling. We then trained a gkm-SVM with default parameters (*l* = 10, *k* = 6, and *d* = 3 with truncated filter), and measured the classification performance using ROC curves with five-fold cross validation. Scaling of performance with gkm-SVM feature length is shown in [Supplementary Figure 5](#SD1){ref-type="supplementary-material"}. To calculate deltaSVM, 10-mer SVM scores were used as a proxy for weights. We generated the final weights by averaging gkm-SVMs trained on five independently generated 1x negative sets. When we compare deltaSVM between different training sets we normalize weights by the standard deviation of the weight distribution, but we have reported raw weights here for simplicity. This correction is typically a small effect (\< 50%).

Training set for DNaseI Hypersensitive regions in lymphoblastoid cell lines {#S8}
---------------------------------------------------------------------------

GM12878 DNaseI-seq peaks were first defined by MACS^[@R43]^ (P \< 1e-9) for each replicate independently. We then chose peaks that were consistently found in both replicates. These peaks were further trimmed and 300 bp central DHSs that maximize the DNase I hypersensitive signals were determined. We also excluded any regions with repeats \> 70% and regions overlapping with dsQTLs, to avoid possible overfitting when scoring dsQTLs. We ultimately obtained 22,384 300 bp DHSs as the positive training set.

Training set for mouse melanocyte enhancers {#S9}
-------------------------------------------

To train gkm-SVM appropriate for Tyr and Tyrp1 enhancers in mouse melanocytes, we determined 4,337 EP300 bound regions in the mouse melanocyte cell line melan-Ink4a-Arf ^[@R12]^ as the positive training set by following the above protocol with some adjustments (MACS P \< 0.002). Promoter proximal regions and repeats were excluded from the training set. Since this positive set is much smaller than the others, we generated 10x larger negative sets in order to obtain more robust weights for deltaSVM analysis.

Training set for mouse liver enhancers {#S10}
--------------------------------------

Similar to the training set for DHSs in LCLs, we defined a positive training set (*n* = 19,590) relevant to the ALDOB enhancer by integrating DNaseI-seq and H3K4me1 ChIP-seq on adult mouse liver tissue^[@R23]^. To specify liver enhancers, we additionally excluded all promoter proximal DHSs (defined as regions with distances to the nearest known transcription start sites (TSS) \< 2 kbp) from the training set, after determining the 300 bp core DHSs as described above. We further selected DHSs that overlap with H3K4me1 ChIP-seq peaks, which are well-known markers for enhancer activity^[@R44],[@R45]^, and defined these as the positive training set.

DeltaSVM analysis of dsQTL SNPs {#S11}
-------------------------------

We used the dsQTL tables and the raw data files downloaded from the GEO database (accession number GSE31388) to define the positive and control sets of dsQTL SNPs. Because association alone does not necessarily imply the causation due in part to LD problem, we further applied more stringent rules to determine the *most likely* causal dsQTL SNPs. We first restricted to 1,296 SNPs within their associated 100 bp DHSs to ensure that the changes in DNase I sensitivities are physically linked to the changes in their DNA sequences. We also applied a more strict association P-value threshold (*P* \< 1e-5) to reduce false positive associations, finally resulting in 579 SNPs. As a control SNP set, we generated a 50x larger set of common random SNPs (*N* = 28,950; minor allele frequency \> 5%) sampled only from the top 5% DHS regions that had been used to identify dsQTLs in the previous study^[@R13]^. To reduce false negative SNPs, we excluded from sampling any DHSs that had been found to be significantly associated with any of the dsQTL SNPs. Weights from gkm-SVM and kmer-SVM trained on the GM12878 DHSs were then used to calculate deltaSVM scores. We confirmed that training a gkm-SVM on negative sequences constrained to match the positive sequences distance to TSS distribution did not affect overall performance ([Supplementary Figure 6](#SD1){ref-type="supplementary-material"}). We further confirmed that using negative dsQTL control SNPs constrained to match the positive dsQTL distance to TSS and LD distribution did not affect overall performance ([Supplementary Figure 7](#SD1){ref-type="supplementary-material"}). As a comparison, we considered three different scoring metrics; Combined-Annotation-Dependent Depletion (CADD^[@R4]^), Genome-Wide Annotation of Variants (GWAVA^[@R5]^), and conservation scores (Genomic Evolutionary Rate Profiling: GERP^[@R16]^). We downloaded pre-computed CADD scores for all 1000 Genome variants, from which the scores for the dsQTLs and control SNPs were extracted. We also extracted the corresponding GWAVA scores from the pre-calculated table downloaded from the GWAVA website. We analyzed all three different GWAVA models (region, tss, and unmatched) and chose the best one (region), as determined by AUC, for the main analysis. The GERP scores were also extracted from the same GWAVA result files. To do a fair comparison, we only considered SNPs for which all the five scores are available, resulting in 574 positive SNPs and 27,735 control SNPs. The entire prediction results are available in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. eQTL beta was calculated using quantile-normalized gene expression from the eQTL website.

Melanocyte Luciferase Assay and deltaSVM analysis {#S12}
-------------------------------------------------

We selected 22 and 23 SNVs for functional testing in the Tyr (mm10 coordinates chr7: 87508164--87508388; 226 bp) and Tyrp1 (mm10 coordinates chr4:80819561--80819851; 291 bp), respectively. These SNVs were randomly selected as follows: 10 SNVs in each enhancer predicted to reduce the enhancer's activity (negative deltaSVM), 4 SNVs in each enhancer predicted to increase the enhancer's activity (positive deltaSVM), 4 in each enhancer SNVs predicted to have a neutral impact on the enhancer's activity (deltaSVM near 0), and 4 (Tyr) or 5 (Tyr) additional SNVs that overlap with key motifs identified in previous reports^[@R20],[@R21]^. Reference and SNV enhancer sequences were synthesized (Genewiz; South Plainfield, NJ), verified by sanger sequencing, and cloned into a luciferase reporter plasmid containing a minimal promoter and a luciferase reporter gene. For each SNV, we performed 4 biological replicates (each with an independent plasmid DNA clone) in order to control for differences that might arise from random mutations in the plasmid backbone or from variation in the quality of plasmid preps. We transfected each reporter plasmid into the mouse melanocyte cell line melan-Ink4a-Arf, and measured luciferase activity 24 hours later using the Dual-Luciferase Reporter Assay System (Promega; Madison, WI). We compared the activity of each variant enhancer sequence to the activity of the reference sequence (normalized to 1), and were thus able to quantitate the impact of each SNV on the enhancer's activity. The entire deltaSVM predictions and the luciferase assay results are provided as [Supplementary Table 2 and 3](#SD1){ref-type="supplementary-material"}, respectively.

deltaSVM Analysis of Massively Parallel Reporter Assays {#S13}
-------------------------------------------------------

To compare with exhaustive single nucleotide mutagenesis of the ALDOB enhancer^[@R22]^, we trained a gkm-SVM on adult mouse liver DHS as described above and scored each single nucleotide variant with deltaSVM and compared them with its measured *in vivo* expression changes ([Supplementary Table 4](#SD1){ref-type="supplementary-material"})^[@R22]^. To compare with the directed mutagenesis of putative K562 and HepG2 enhancers^[@R24]^, we trained K562 an HepG2 specific gkm-SVMs on the top 10000 500 bp DHS regions in K562 and HepG2 cells^[@R8]^, after excluding regions that were DHS in more than 30% of human ENCODE cell lines, or near promoters (\< 2 kb from TSS), against an equal size GC and repeat matched training set. We compared deltaSVM and the expression change for pair of mutant wild-type constructs for each wild-type construct significantly expressed in either cell line (mean normalized expression\>3.5) which yielded 175 wild-type constructs and 277 mutant constructs: 102 of these are single base pair mutations and 175 are motif scrambling (8--17 bp changed) ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). For the motif scrambling mutations we summed all 10-mer scores spanning the mutated motif.

Training set for validated enhancers {#S14}
------------------------------------

For each appropriate cell line, we trained on the top 10,000 500 bp DHS regions, after excluding regions that were DHS in more than 30% of human/mouse ENCODE cell lines/tissues, or near promoters (\< 2 kb from TSS), against an equal size GC and repeat matched training set. The cell lines chosen were human LNCaP^[@R8]^ for *Rfx6*, mouse erythroleukemia (MEL)^[@R23]^ cells for *Bcl11a*, and HepG2^[@R8]^ cells for *Sort1*.

Scoring of Autoimmune variants {#S15}
------------------------------

We selected 11 autoimmune traits enriched in Th1 H3K27Ac as shown in Fig 3 of Ref. ^[@R28]^. We made predictions for 413 lead SNPs associated with 11 autoimmune diseases enriched in Th1 H3K27Ac regions (T1D: Type 1 Diabetes, CRO: Crohn's Disease, MS: Multiple Sclerosis, CEL: Celiac Disease, PBC: Primary Biliary Cirrhosis, RA: Rheumatoid Arthritis, Allergy, ATD: Autoimmune Thyroid Disease, UC: Ulcerative Colitis, VIT: Vitiligo, SLE: Systemic Lupus Erythematosus)^[@R28]^. We trained a gkm-SVM on the top 10,000 500 bp Th1 DHS regions, after excluding regions that were DHS in more than 30% of human ENCODE cell lines, or near promoters (\< 2 kb from TSS), against an equal size GC and repeat matched training set. We scored the lead SNP and all flanking off-lead candidates in LD as defined by (R^2^ \> .5 and PICS^[@R28]^ probability \> .0275), yielding 3113 total SNPs. Since the significance of the maximum deltaSVM score in a locus will depend on the number of SNPs in that locus, as a random control we scored random SNPs and equal size flanking sets. To determine the cutoff, we first determined 2^nd^ percentile deltaSVM score from 10,000 random permutations for each number of flanking SNPs (1\~30), and then calculated mean and standard deviation of the 100 repeated experiments as the final cutoff. We identified 17 high scoring deltaSVM SNPs which we predict to be expression perturbing SNPs with high confidence (P \< .02), while at this threshold random sampling produced 8 SNPs (binomial test P \< 0.004, [Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). deltaSVM scores for all 3113 SNPs are provided as [Supplementary Table 6](#SD1){ref-type="supplementary-material"}.

Supplementary Material {#S16}
======================

###### 

**Supplementary Table 1:** All predictions of the 574 dsQTL SNPs and the 27735 control SNPs.

**Supplementary Table 2:** deltaSVM predictions of all possible point mutations in Tyr and Tyrp1 enhancers.

**Supplementary Table 3:** Experimental validation results of randomly selected deltaSVM predictions from Tyr and Typr1 enhancers.

**Supplementary Table 4:** deltaSVM predictions of all possible single point mutations in ALDOB enhancer and the corresponding *in vivo* effect size.

**Supplementary Table 5:** deltaSVM predictions of mutations in K562 and HepG2 enhancers.

**Supplementary Table 6**: deltaSVM predictions of all 3113 autoimmune disease associated SNPs.
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![Overview of our deltaSVM method\
\[left\] The first step in calculating deltaSVM is to train a gkm-SVM classifier using a positive training set of putative regulatory sequences (identified by DNase I hypersensitivity, for example) and a negative training set of matched negative control sequences. The gkm-SVM generates a regulatory sequence vocabulary -- a weighted list of all possible 10-mers, where each 10-mer receives an SVM weight that quantifies its contribution to the prediction of regulatory function. \[right\] After training, this regulatory sequence vocabulary can be used to score the predicted impact of any sequence variant on regulatory activity, as shown here for a single nucleotide substitution in a melanocyte enhancer of the *Tyrp1* enhancer.](nihms689528f1){#F1}

![deltaSVM can accurately predict SNPs associated with DNaseI Hypersensitivity\
(**a**) An example of a deltaSVM calculation using a known dsQTL SNP (rs4953223). (**b**) 10-mer gkm-SVM scores across the dsQTL locus containing rs4953223 are shown. Only the functional SNP produces dramatic changes in gkm-SVM scores. (**c**) Effect sizes of dsQTL SNPs from Ref. ^[@R13]^ are well correlated with their deltaSVM scores. (**d--e)** deltaSVM predicts dsQTLs with far greater accuracy than existing methods. Discriminative powers are compared between various methods using 50x larger control SNP set. (**d**) ROC curve. (**e**) Precision-Recall curve.](nihms689528f2){#F2}

![deltaSVM is strongly positively correlated with dsQTL effect size, and positively or negatively correlated with eQTL effect size depending on the sign of the correlation of dsQTL and eQTL\
Degner et al reported that 16% of the dsQTLs were also eQTLs, but that 30% of the eQTL dsQTLs were anti-correlated with the expression change. Our predictions are consistent with this observation: (**a**) deltaSVM is always positively correlated with dsQTL effect size (beta), (**b**) but because eQTL beta and dsQTL beta are anti-correlated 30% of the time, (**c**) deltaSVM and eQTL beta are only correlated (positively and negatively) if we treat the activating dsQTLs (red) and repressive dsQTLs (blue) separately. (**d**) Bases predicted to reduce the activity of functional regions are evolutionarily constrained.](nihms689528f3){#F3}

![deltaSVM accurately predicts change in luciferase expression in targeted mutagenesis of Tyr and Tyrp1 melanocyte enhancers\
**(a**,**b)** Base by base evaluation of all possible substitutions as scored by deltaSVM. Black circles mark substitutions that were tested in luciferase assays. Orange bars show positions of the previously characterized binding sites. (**c**,**d**) Correlation of deltaSVM prediction and observed normalized luciferase expression. Blue circles indicate previously tested binding site^[@R20],[@R21]^. Error bar is one standard deviation of the changes in luciferase expression (4 biological replicates per variant).](nihms689528f4){#F4}

![deltaSVM accurately predicts change of expression in massively parallel reporter assays\
**(a**) Correlations of deltaSVM predictions and observed *in vivo* mutation effect size in the ALDOB enhancer in mice^[@R22]^. (**b**) Correlation of deltaSVM and mutated enhancers in K562 cells^[@R24]^. (**c**) Correlation of deltaSVM and mutated enhancers in HepG2 cells^[@R24]^.](nihms689528f5){#F5}

![deltaSVM only identifies validated causal SNPs when trained on the appropriate cell type\
**(a)** Three validated GWAS SNPs from Rfx6 (1^st^ column), Bcl11a (2^nd^ column), and Sort1 (3^rd^ column) and flanking negative SNPs were each scored with deltaSVM trained on all three relevant cell-types. The validated SNPs are properly identified from among flanking SNPs when trained on the appropriate cell type (red) but not other cell types (blue). (**b,c**) Scoring autoimmune GWAS loci with deltaSVM trained on Th1 yields high confidence causal SNPs listed in [Table 2](#T2){ref-type="table"}. BACH2 locus is shown in (**b**) as an example. Error bar in (**c**) is one standard deviation of the expected binomial distribution.](nihms689528f6){#F6}

###### Cell-type specificity of deltaSVM predictions

We compare weights trained on all five cell types to the measured expression changes in all five cell lines. P-values are in parenthesis. Although some TFs are active in more than one cell type, we generally observe that deltaSVM predictions are cell-type specific.

  Gkm-SVM                   LCL-dsQTL              Tyr                 Tyrp1               Aldob                  K562 enhancers         HepG2 enhancers
  ------------------------- ---------------------- ------------------- ------------------- ---------------------- ---------------------- ----------------------
  **GM12878 DHS**           **0.721 (7.68e-94)**   0.302 (0.172)       0.117 (0.595)       0.112 (0.00256)        0.204 (0.00062)        0.201 (0.00076)
  **Mouse melan-a EP300**   0.245 (2.19e-9)        **0.78 (2.0e-5)**   **0.53 (0.0095)**   0.147 (7.42e-5)        0.204 (0.00062)        0.194 (0.00116)
  **Mouse liver DHS**       0.131 (0.00157)        0.282 (0.203)       0.056 (0.798)       **0.630 (3.24-e81)**   −0.329 (2.04e-8)       0.551 (2.07e-23)
  **K562 DHS**              0.581 (1.45e-53)       0.390 (0.0726)      0.104 (0.638)       0.092 (0.0137)         **0.626 (1.34e-31)**   −0.042 (0.483)
  **HepG2 DHS**             0.518 (3.84e-41)       0.551 (0.00791)     0.166 (0.450)       0.547 (1.01e-57)       −0.184 (.0021)         **0.646 (3.84e-34)**

###### deltaSVM predicted causal autoimmune SNPs

Scoring autoimmune GWAS loci with deltaSVM trained on Th1 yields predictions for high confidence causal SNPs.

  Disease   Lead SNP     Predicted SNP   CHR     Lead SNP Position   Predicted SNP Position   Distance   Nearset Gene   \|deltaSVM\|   Ref.
  --------- ------------ --------------- ------- ------------------- ------------------------ ---------- -------------- -------------- ----------------------------
  VIT       rs853308     rs860475        chr8    133929917           133929799                −118       TG             16.797         ^[@R29]^
  VIT       rs16872571   rs4697651       chr4    10726853            10721433                 −5420      .              13.978         ^[@R29]^
  T1D       rs7020673    rs4380994       chr9    4291747             4282536                  −9211      GLIS3          13.591         ^[@R30]^
  CRO       rs6908425    rs7748720       chr6    20728731            20689945                 −38786     CDKAL1         13.177         ^[@R31],[@R32]^
  MS        rs1782645    rs1250568       chr10   81048611            81045280                 −3331      ZMIZ1          11.039         ^[@R33]^
  CEL       rs1250552    rs1250568       chr10   81058027            81045280                 −12747     ZMIZ1          11.039         ^[@R34]^
  CRO       rs10801047   rs6665749       chr1    191559356           191577594                18238      .              10.646         ^[@R35]^
  CRO       rs2797685    rs2797685       chr1    7879063             7879063                  0          PER3           10.411         ^[@R31]^
  Allergy   rs962993-T   rs962993        chr10   9053132             9053132                  0          .              10.008         ^[@R36]^
  PBC       rs10931468   rs3771317       chr2    191538562           191543962                5400       NAB1           9.999          ^[@R37]^
  CEL       rs7753008    rs72928038      chr6    90809639            90976768                 167129     BACH2          9.787          ^[@R38]^
  RA        rs72928038   rs72928038      chr6    90976768            90976768                 0          BACH2          9.787          ^[@R39],\ [@R40],\ [@R33]^
  ATD                                                                                                                                  
  MS                                                                                                                                   
  MS        rs564976     rs485789        chr3    159729059           159730148                1089       AK097161       8.782          
  MS        rs733724     rs733724        chr6    105223864           105223864                0          HACE1          7.360          ^[@R41]^
  PBC       rs3024921    rs3024921       chr2    191943272           191943272                0          STAT4          6.931          ^[@R42]^
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